QuickLinks -- Click here to rapidly navigate through this document

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of ~~April~~May, 2004

Commission File Number: 001-10378

AVENTIS
(Translation of registrant's name into English)

67917 Strasbourg CEDEX 9
France
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ý Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No ý

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable

EXHIBIT LIST

Exhibit		Description
99.1		English translation of the French "Note d'Information en réponse" of Aventis filed with the Autorité des marchés financiers in response to Sanofi-Synthélabo's improved offer.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AVENTIS (Registrant)
		AVENTIS(Registrant)
Date: April 30, 2004	By:	/s/ DIRK OLDENBURG Name: Dirk Oldenburg Title: General Legal Counsel
Date: May 28, 2004	By:	/s/ DIRK OLDENBURG Name: Dirk Oldenburg Title: General Legal Counsel

EXHIBIT LIST

Exhibit		Description
99.1		Transcript from Aventis' First Quarter 2004 Results conference call held on April 29, 2004.
99.2		Transcript from Aventis' First Quarter 2004 Results U.S. conference call held on April 29, 2004.
99.3		Press Release, dated April 1, 2004, relating to the completion of Aventis' divestment of Aventis Behring.
99.4		Press Release, dated April 1, 2004, relating to the FDA's denial of Public Citizen Petition regarding Arava.
99.5		Press Release issued by Aventis on April 26, 2004.

QuickLinks

EXHIBIT LIST
Signatures

Filing Compare · AVENTIS